# Phase 2 obesity trials recruiting: 102 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 102 trials in phase 2 for obesity that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 obesity trials: 102 rows for $5.10, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 6 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/obesity

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 102
- Recruiting or not yet: 102
- Read on: November 19, 2026

## Trials

The 25 newest of 102, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07946796 | Semaglutide Effects on Sperm Concentration in Overweight Infertile Men | Copenhagen University Hospital at Herlev | Phase 2 | Not yet recruiting | Infertility in Overweight Men | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07946796) |
| November 18, 2026 | NCT07946315 | Tirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension | Brigham and Women's Hospital | Phase 2 | Not yet recruiting | Idiopathic Intracranial Hypertension (IIH), Pseudotumor Cerebri, Papilledema | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07946315) |
| November 10, 2026 | NCT07929298 | A Study to Evaluate the Safety and Efficacy of Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity | Hangzhou Sciwind Biosciences Co., Ltd. | Phase 2 | Not yet recruiting | Overweight , Obesity, Weight Management | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07929298) |
| November 2, 2026 | NCT07909889 | Semaglutide for Weight Management During Hormone Therapy for Early Breast Cancer | Aarhus University Hospital | Phase 2 | Not yet recruiting | Breast Cancer (Early Breast Cancer), Obesity | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909889) |
| October 29, 2026 | NCT07902752 | Oxytocin for Respiratory Compromise and Hypoventilation Induced by Drugs | George Washington University | Phase 2 | Not yet recruiting | Obesity & Overweight, Respiratory Depression, Intranasal Drug Administration, Oxytocin, Bariatric Surgery | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07902752) |
| October 22, 2026 | NCT07890376 | A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes | Eli Lilly and Company | Phase 2 | Not yet recruiting | Obesity, Overweight | 460 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890376) |
| October 20, 2026 | NCT07884058 | IGOB131 As A GLP-1 Modulator For Metabolic Disorders In Adults With Obesity | University of Yaounde 1 | Phase 2 | Not yet recruiting | Obesity & Overweight | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07884058) |
| October 20, 2026 | NCT07882654 | A PHASE 2A, EXPLORATORY, RANDOMIZED, SINGLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY OF WEIGHT LOSS INDUCED BY NKS-3 IN... | EktaH | Phase 2 | Not yet recruiting | Obesity / Overweight, Obesity (BMI Equal to or \>30) | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07882654) |
| October 15, 2026 | NCT07874828 | PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A... | M.D. Anderson Cancer Center | Phase 2 | Recruiting | Sarcoma,Soft Tissue | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874828) |
| October 5, 2026 | NCT07857473 | A Study to Investigate the Safety and Efficacy of TE-8105 in Overweight or Obesity Participants | Immunwork, Inc. | Phase 2 | Not yet recruiting | Overweight and Obesity | 204 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07857473) |
| September 24, 2026 | NCT07837973 | Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss | Alveus Therapeutics, Inc. | Phase 2 | Recruiting | Overweight , Obesity, Adults | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07837973) |
| September 21, 2026 | NCT07830329 | Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or... | Regeneron Pharmaceuticals | Phase 2 | Recruiting | Hidradenitis Suppurativa | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07830329) |
| September 16, 2026 | NCT07823452 | Supplementation of Gut-brain Axis (GLP-1)-Activating Carbohydrates for Increasing Satiety in Adolescents With Obesity | Indiana University | Phase 2 | Not yet recruiting | Obesity & Overweight | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07823452) |
| September 15, 2026 | NCT07820358 | Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer | The Methodist Hospital Research Institute | Phase 2 | Not yet recruiting | Endometrial Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial... | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07820358) |
| September 10, 2026 | NCT07812597 | A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ) | Beijing QL Biopharmaceutical Co.,Ltd | Phase 2 | Not yet recruiting | Obesity | 210 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07812597) |
| September 4, 2026 | NCT07803991 | Efficacy and Safety of SYH2069 Injection in Obese Participants Without Diabetes. | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Overweight or Obesity | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07803991) |
| August 25, 2026 | NCT07783802 | A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event | Eli Lilly and Company | Phase 2 | Recruiting | Atherosclerosis, Cardiovascular Disease, Obesity, Hypertension, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07783802) |
| August 24, 2026 | NCT07781150 | Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer | Tongji Hospital | Phase 2 | Not yet recruiting | Obesity, Overweight, Atypical Endometrial Hyperplasia, Endometrial Carcinoma Stage I, Endometrioid Endometrial Cancer | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07781150) |
| August 12, 2026 | NCT07760948 | HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide | Vanderbilt University Medical Center | Phase 2 | Not yet recruiting | Type 2 Diabetes Mellitus (T2DM), Sarcopenia, Obesity, Muscle Loss, Older Adults | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07760948) |
| August 10, 2026 | NCT07754045 | Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults | Lumos Pharma | Phase 2 | Not yet recruiting | Obesity & Overweight | 202 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07754045) |
| August 7, 2026 | NCT07752979 | Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities | AbbVie | Phase 2 | Recruiting | Obesity, Overweight | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07752979) |
| August 5, 2026 | NCT07747805 | GLP-1 Agonists for Lung Function Improvement and Muscle Restoration in COPD | The Cleveland Clinic | Phase 2 | Not yet recruiting | COPD, Obesity & Overweight, Sarcopenia | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07747805) |
| July 28, 2026 | NCT07731256 | Semaglutide for Low Back Pain | Washington University School of Medicine | Phase 2 | Not yet recruiting | Lower Back Pain, Obesity (BMI\>30), Chronic Lower Back Pain, glp1 Agonist | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07731256) |
| July 8, 2026 | NCT07690826 | A Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in Obesity | Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Overweight or Obesity | 252 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07690826) |
| July 6, 2026 | NCT07685808 | Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes | Regeneron Pharmaceuticals | Phase 2 | Recruiting | Overweight or Obesity | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07685808) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 5 |
| University of Colorado, Denver | 4 |
| Massachusetts General Hospital | 3 |
| Washington University School of Medicine | 3 |
| Johns Hopkins University | 2 |
| University of Oklahoma | 2 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 2 |
| Hudson Biotech | 2 |
| [Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/hangzhou-zhongmei-huadong-pharmaceutical-co-ltd) | 2 |
| The University of Texas Health Science Center, Houston | 2 |
| The Cleveland Clinic | 2 |
| [Guangdong Raynovent Biotech Co., Ltd](https://specstream.ai/data/clinical-trials/company/guangdong-raynovent-biotech-co-ltd) | 1 |
| Yale University | 1 |
| Biomed Industries, Inc. | 1 |
| VA Office of Research and Development | 1 |
| Indiana University | 1 |
| Cairo University | 1 |
| S1 Biopharma, Inc. | 1 |
| First Affiliated Hospital of Wenzhou Medical University | 1 |
| Ruijin Hospital | 1 |
| Vanderbilt University Medical Center | 1 |
| NeuroBiogen Co., Ltd | 1 |
| The University of Texas Health Science Center at San Antonio | 1 |
| The Methodist Hospital Research Institute | 1 |
| St. Jude Children's Research Hospital | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 59 |
| China | 15 |
| Australia | 4 |
| Canada | 4 |
| Puerto Rico | 3 |
| Denmark | 3 |
| Argentina | 3 |
| Egypt | 2 |
| Poland | 2 |
| New Zealand | 1 |
| South Korea | 1 |
| Spain | 1 |
| Japan | 1 |
| Germany | 1 |
| United Kingdom | 1 |
| Tunisia | 1 |
| Belgium | 1 |
| Greece | 1 |
| Serbia | 1 |
| France | 1 |
| Georgia | 1 |
| Czechia | 1 |
| Hong Kong | 1 |
| Moldova | 1 |
| Romania | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Contract law firms in the United States](https://specstream.ai/data/businesses/contract-law-firms/united-states)
- [Electrical supply stores in the United States](https://specstream.ai/data/businesses/electrical-supply-stores/united-states)
- [Fondue restaurants in the United States](https://specstream.ai/data/businesses/fondue-restaurants/united-states)
- [Hospices in the United States](https://specstream.ai/data/businesses/hospices/united-states)
- [Laboratories in the United States](https://specstream.ai/data/businesses/laboratories/united-states)
- [Mobility equipment companies in the United States](https://specstream.ai/data/businesses/mobility-equipment-companies/united-states)
